ZA200608878B - Transdermal steroid formulation - Google Patents

Transdermal steroid formulation

Info

Publication number
ZA200608878B
ZA200608878B ZA200608878A ZA200608878A ZA200608878B ZA 200608878 B ZA200608878 B ZA 200608878B ZA 200608878 A ZA200608878 A ZA 200608878A ZA 200608878 A ZA200608878 A ZA 200608878A ZA 200608878 B ZA200608878 B ZA 200608878B
Authority
ZA
South Africa
Prior art keywords
sup
group
weight
steroid formulation
acrylate
Prior art date
Application number
ZA200608878A
Other languages
English (en)
Inventor
Murray James Robert
Kamiyama Fumio
Wuelfert Ernst
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of ZA200608878B publication Critical patent/ZA200608878B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200608878A 2004-04-28 2006-10-25 Transdermal steroid formulation ZA200608878B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0409498.3A GB0409498D0 (en) 2004-04-28 2004-04-28 Transdermal steroid formulation

Publications (1)

Publication Number Publication Date
ZA200608878B true ZA200608878B (en) 2008-07-30

Family

ID=32408193

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608878A ZA200608878B (en) 2004-04-28 2006-10-25 Transdermal steroid formulation

Country Status (25)

Country Link
US (1) US20070231373A1 (da)
EP (1) EP1748779B1 (da)
JP (1) JP4849478B2 (da)
KR (1) KR101139023B1 (da)
CN (1) CN1997375B (da)
AT (1) ATE480241T1 (da)
AU (1) AU2005237285B2 (da)
CA (1) CA2563830C (da)
CY (1) CY1111318T1 (da)
DE (1) DE602005023436D1 (da)
DK (1) DK1748779T3 (da)
ES (1) ES2352202T3 (da)
GB (1) GB0409498D0 (da)
HK (1) HK1096606A1 (da)
HR (1) HRP20100558T1 (da)
IL (1) IL178781A (da)
NO (1) NO337073B1 (da)
NZ (1) NZ550784A (da)
PL (1) PL1748779T3 (da)
PT (1) PT1748779E (da)
RU (1) RU2371183C2 (da)
SI (1) SI1748779T1 (da)
TW (1) TWI354557B (da)
WO (1) WO2005105104A1 (da)
ZA (1) ZA200608878B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523550D0 (en) * 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
PL2097079T3 (pl) * 2006-11-30 2012-11-30 Hunter Fleming Ltd Modulowanie szlaków metabolicznych prostaglandyna/cyklooksygenaza

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE58909570D1 (de) * 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
DE69427815T2 (de) * 1993-05-18 2001-11-08 Ltt Institute Co., Ltd. Osteogenese-promoter und mittel gegen osteoporose
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
EP0827405A2 (en) * 1995-05-15 1998-03-11 Beth Israel Hospital Use of dihydrotestosterone compounds for treating male sexual dysfunction
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US20010023261A1 (en) * 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
KR100215027B1 (ko) * 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
DE19728517C2 (de) * 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Sexualsteroidhormonen und Verfahren zu seiner Herstellung
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
DK1322336T3 (da) * 2000-08-30 2013-07-15 Unimed Pharmaceuticals Llc Fremgangsmåde til forøgelse af testosteron og beslægtede steroidkoncentrationer hos kvinder
FR2818148B1 (fr) * 2000-12-15 2005-06-24 Oreal Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide
US6510801B2 (en) * 2001-06-01 2003-01-28 Hong Sin Tan Pallet for shrinkwrapped packaging of block rubber
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
US7456236B2 (en) * 2003-03-27 2008-11-25 Cosmed Pharmaceutical Co., Ltd. Adhesive for percutaneous absorption, adhesive composition for percutaneous absorption and preparation for percutaneous absorption

Also Published As

Publication number Publication date
CN1997375A (zh) 2007-07-11
NO337073B1 (no) 2016-01-18
JP2007534734A (ja) 2007-11-29
DE602005023436D1 (de) 2010-10-21
DK1748779T3 (da) 2010-12-13
CA2563830C (en) 2013-01-15
US20070231373A1 (en) 2007-10-04
JP4849478B2 (ja) 2012-01-11
ATE480241T1 (de) 2010-09-15
RU2006141830A (ru) 2008-06-10
KR101139023B1 (ko) 2012-04-26
EP1748779B1 (en) 2010-09-08
IL178781A0 (en) 2007-05-15
AU2005237285A1 (en) 2005-11-10
IL178781A (en) 2013-10-31
RU2371183C2 (ru) 2009-10-27
NZ550784A (en) 2010-03-26
SI1748779T1 (sl) 2011-01-31
HRP20100558T1 (hr) 2010-11-30
EP1748779A1 (en) 2007-02-07
TWI354557B (en) 2011-12-21
PT1748779E (pt) 2010-11-02
AU2005237285B2 (en) 2010-10-14
CN1997375B (zh) 2010-09-22
CY1111318T1 (el) 2015-08-05
KR20070004995A (ko) 2007-01-09
HK1096606A1 (en) 2007-06-08
TW200538133A (en) 2005-12-01
WO2005105104A1 (en) 2005-11-10
CA2563830A1 (en) 2005-11-10
ES2352202T3 (es) 2011-02-16
GB0409498D0 (en) 2004-06-02
NO20065440L (no) 2006-11-27
PL1748779T3 (pl) 2011-03-31

Similar Documents

Publication Publication Date Title
TW200504169A (en) Pressure-sensitive adhesive for surface-protective film and surface-protective film
TW200724635A (en) Acrylic pressure-sensitive adhesive composition
EP2135908A3 (en) Pressure-sensitive adhesive composition and pressure-sensitive adhesive sheet to be attached to metal surface
EP2135906A3 (en) Pressure-sensitive adhesive composition and use thereof
EP2135907A3 (en) Pressure-sensitive adhesive composition, pressure-sensitive adhesive sheet, and method for producing the same
ZA201002433B (en) Aqueous dispersions including at least one alkyd resin and at least one addition polymer having at least one (meth)acrylate segment
WO2009005118A1 (ja) アクリル系粘弾性組成物、及び感圧性接着テープ又はシート
EP2153827A3 (en) Composition for the Transdermal Delivery of Fentanyl
EP2492330A3 (en) Removable Water-Dispersible Acrylic Pressure-Sensitive Adhesive Composition and Pressure-Sensitive Adhesive Sheet
HK1150619A1 (en) Fluoropolymer emulsions
ATE404250T1 (de) Copolymere auf basis von tert.-butyl(meth)acrylat und deren verwendung in haarsprays
EP2048213A4 (en) FULL TASTING COMPOSITION AND LABEL FROM THIS
WO2009120412A3 (en) Adhesive composition having non-tacky microspheres and sheets made therefrom
ATE508166T1 (de) Copolymermischung
TW200801147A (en) High-strength adhesive polymer gel and adhesive tape
TW200602448A (en) Thermosetting adhesive or pressure-sensitive adhesive composition and thermosetting adhesive or pressure-sensitive adhesive tape or sheet
DE602005008189D1 (de) Haftklebstoffzusammensetzung und hautpflaster
MY160559A (en) Adhesive and adhesive sheet
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
EP2324860A3 (en) Medical pressure-sensitive adhesive composition
DE602005020996D1 (de) Kaugummi und gummibasis enthaltend styrol-isopren-styrol-copolymere
MX2010007987A (es) Composiciones fotoprotectoras mejoradas.
HK1096606A1 (en) Transdermal steroid formulation
US10849859B2 (en) Acrylic polymers and their use in transdermal drug delivery
PL1694320T3 (pl) Zastosowanie kompozycji zawierających kwas oleanolowy i kwas ursolowy do wytwarzania leku do leczenia nadwrażliwości i nadreaktywności